SCHEMBL10018282

SCHEMBL10018282

C=CCOC(=O)NCC(C)(C)C(=O)SCCO

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10018290 0.91 TDP1 (0.33) SMN1; SMN2
SCHEMBL10050039 0.86 ACHE (0.31) SMN1; SMN2
SCHEMBL15634844 0.82 CYP4F2 (0.35) SMN1; SMN2KMT2A
SCHEMBL20058601 0.81 TDP1 (0.31)
SCHEMBL10018267 0.80
SCHEMBL10049881 0.80 SMN1; SMN2 (0.33) SMN1; SMN2MEN1KMT2A
SCHEMBL10018274 0.78
SCHEMBL12975284 0.74 BRD4 (0.32)
SCHEMBL17410559 0.72 TDP1 (0.33) SMN1; SMN2KMT2A
SCHEMBL15634197 0.69 ACHE (0.37) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142763-A1 NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-06-07 US disclosed
US-20120142763-A1 NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142763-A1 NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF NSUN3, NSUN2, DIS3 SMN1; SMN2 265/4885MEN1 1563/4885KMT2A 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.